ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

9 links0 made here, not in the record19 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05601440Liquid-biopsy InformedPlatform Trial to EvaluateCDK4/6-inhibitor ResistantER+/HER2- Metastatic BreastCancerCanadian Cancer Trials GroupPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSLunresertibEntry “RP-6306”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedGemcitabineIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNiraparibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFulvestrantIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedBackground · partnerCamonsertibEntry “RP-3500”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCFI-402257Intervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOcifisertib fumarateEntry “CFI-400945”, read by our name …›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSacituzumab govitecanIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Lunresertib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “RP-6306”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3LunresertibClaude Opus 5.5TestedCurrent
Nov 3GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 3NiraparibClaude Opus 5.5TestedCurrent
Nov 3FulvestrantClaude Opus 5.5TestedReplaced
Nov 3CamonsertibClaude Opus 5.5TestedCurrent
Nov 3CFI-402257Claude Opus 5.5TestedCurrent
Nov 3Ocifisertib fumarateClaude Opus 5.5TestedCurrent
Nov 3Sacituzumab govitecanClaude Opus 5.5TestedReplaced
Nov 3FulvestrantClaude Opus 5.5Background · partnerCurrent
Nov 3Sacituzumab govitecanClaude Opus 5.5TestedCurrent
Nov 18LunresertibRule based · role ruleTestedAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18NiraparibRule based · role ruleTestedAgrees
Nov 18FulvestrantRule based · role ruleTestedOverridden
Nov 18CamonsertibRule based · role ruleTestedAgrees
Nov 18CFI-402257Rule based · role ruleTestedAgrees
Nov 18Ocifisertib fumarateRule based · role ruleTestedAgrees
Nov 18Sacituzumab govitecanRule based · role ruleTestedAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.